上海医药：产品“硫酸羟氯喹片”取得注册证

Group 1 - Shanghai Pharmaceuticals announced that its subsidiary, Shanghai Shiyou Zhongxi Pharmaceutical Co., Ltd., received a drug registration certificate from the Philippines Food and Drug Administration for Hydroxychloroquine Sulfate Tablets, allowing the product to be marketed [1] - For the first half of 2025, Shanghai Pharmaceuticals' revenue composition is as follows: distribution accounts for 91.5%, industrial for 8.59%, retail for 2.97%, other businesses for 0.34%, and other for 0.08% [1] - As of the report date, Shanghai Pharmaceuticals has a market capitalization of 66.6 billion yuan [1]